Tesla is working on new battery cell designs, and a way to make their own cells, with R&D teams in a lab near its car plant in Fremont, California.Technologyread more
The Federal Reserve and the market are miles apart on interest rate expectations, and the disparity could cost the stock market a 7%-10% drop, economists say.Economyread more
Underneath the impressive market rally is a trend that doesn't seem quite right, according to J.P. Morgan.Marketsread more
JP Morgan's Jamie Dimon says student lending "is a disgrace and it's hurting America."Economyread more
Bitcoin topped the $13,000 level Wednesday, rallying to its highest price since January 2018.Bitcoinread more
Wayfair drew backlash and calls from some customers for a boycott after employees protested the company's apparent sale of $200,000 of mattresses and bunk beds destined for a...Retailread more
The shutdown of the fire-damaged Philadelphia Energy Solutions refining complex could send gasoline prices higher across the U.S., but particularly in the mid-Atlantic region...Market Insiderread more
During the foreclosure crisis, investors transformed the single-family home rental market into a formally managed asset class. Now they want new homes.Real Estateread more
The president raised $6 million alone at a fundraiser he attended at the Trump International Hotel on Tuesday in Washington.Politicsread more
The first debates will give most of the contenders their biggest platform yet to present themselves to the American people.Politicsread more
President Trump lambastes Twitter, Google and other technology giants for what he claims as their efforts to stifle him.US Economyread more
In January, Bristol-Myers Squibb announced its plans to buy cancer drugmaker Celgene in a cash and stock deal valued at $74 billion.
Wellington Management is the largest institutional holder of Bristol's common stock at about 8 percent. Wellington said in a release that it "does not believe that the Celgene transaction is an attractive path towards" business that "secures differentiated science and broadens the future revenue base."
Wellington said the acquisition asks Bristol's shareholders to accept too much risk while there are other paths to create value for shareholders. The investment company also worries the execution of the acquisition will be more difficult than depicted by company management.
Furthermore, Wellington said the terms of the agreement offer "Bristol shares to Celgene shareholders at a price well below implied asset value."
Bristol-Myers said since announcing the Celgene transaction on January 3, its board and management team have had numerous meetings and conversations with shareholders, including Wellington.
"We believe that we are acquiring Celgene at an attractive price, and that this transaction presents an important and unique opportunity to create sustainable value," Bristol-Myers said in a statement.
Bristol said it looking forward to its stockholder meeting in April to deliver "the enhanced value this combination creates."
The two companies started talking about the deal Sept. 2018, when Bristol approached Celgene.
Celgene has also been working on an experiential gene therapy that is a highly competitive and potentiality profitable area of the biotech industry. Buying Celgene gives Bristol access to cancer drugs, an area Bristol struggles with in comparison to its rival Merck.